

Documents

Simon, J.^a, Perez-Rivas, L.G.^a, Zhao, Y.^b, Chasseloup, F.^c, Lasolle, H.^d, Cortet, C.^e, Descotes, F.^f, Villa, C.^g, Baussart, B.^h, Burman, P.ⁱ, Maiter, D.^j, von Selzam, V.^a, Rotermund, R.^k, Flitsch, J.^k, Thorsteinsdottir, J.^l, Jouanneau, E.^m, Buchfelder, M.^b, Chanson, P.^c, Raverot, G.^d, Theodoropoulou, M.^a

Prevalence and clinical correlations of SF3B1 variants in lactotroph tumours
(2023) *European Journal of Endocrinology*, 189 (3), pp. 372-378. Cited 1 time.

DOI: 10.1093/ajendo/lvad114

^a Medizinische Klinik und Poliklinik IV, LMU Klinikum, LMU München, Munich, 80336, Germany

^b Department of Neurosurgery, University of Erlangen-Nürnberg, Erlangen, 91054, Germany

^c Université Paris-Saclay, Inserm, Physiologie et Physiopathologie Endocrinienne, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Service d'Endocrinologie et des Maladies de la Reproduction, Centre de Référence des Maladies Rares de l'Hypophyse, Le Kremlin-Bicêtre, 94275, France

^d Endocrinology Department, Reference Center for Rare Pituitary Diseases HYPO, Claude Bernard Lyon 1 University, "Groupement Hospitalier Est" Hospices Civils de Lyon, Bron, 69500, France

^e Service d'Endocrinologie, CHRU de Lille, Lille, 59037, France

^f Service de Biochimie Biologie Moléculaire, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Pierre Bénite, Cedex 69495, France

^g Neuropathology Department, Pitié-Salpêtrière University Hospital, AP-HP, Sorbonne Université, Université Paris Cité, CNRS UMR8104, INSERM U1016, Institut Cochin, Paris, 75014, France

^h Department of Neurosurgery, Assistance Publique-Hopitaux de Paris, Pitié-Salpêtrière University Hospital, Université Paris Cité, CNRS UMR8104, INSERM U1016, Institut Cochin, Paris, 75014, France

ⁱ Department of Endocrinology, Skåne University Hospital, Lund University, Malmö, 214 28, Sweden

^j Department of Endocrinology and Nutrition, UCLouvain Cliniques Universitaires Saint-Luc, Bruxelles, 1200, Belgium

^k Department of Neurosurgery, Division of Pituitary Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, 20251, Germany

^l Neurochirurgische Klinik und Poliklinik, LMU Klinikum, LMU München, Munich, 81377, Germany

^m Pituitary and Skull Base Neurosurgical Department, Reference Center for Rare Pituitary Diseases HYPO, "Groupement Hospitalier Est" Hospices Civils de Lyon, "Claude Bernard" Lyon 1 University, Hôpital Pierre Wertheimer, Bron, Lyon, 69677, France

Abstract

Objective: A somatic mutational hotspot in the SF3B1 gene was reported in lactotroph tumours. The aim of our study was to examine the prevalence of driver SF3B1 variants in a multicentre independent cohort of patients with lactotroph tumours and correlate with clinical data. **Design and methods:** This was a retrospective, multicentre study involving 282 patients with lactotroph tumours (including 6 metastatic lactotroph tumours) from 8 European centres. We screened SF3B1 exon 14 hotspot for somatic variants using Sanger sequencing and correlated with clinicopathological data. **Results:** We detected SF3B1 variants in seven patients with lactotroph tumours: c.1874G > A (p.Arg625His) (n = 4, 3 of which metastatic) and a previously undescribed in pituitary tumours variant c.1873C > T (p.Arg625Cys) (n = 3 aggressive pituitary tumours). In two metastatic lactotroph tumours with tissue available, the variant was detected in both primary tumour and metastasis. The overall prevalence of likely pathogenic SF3B1 variants in lactotroph tumours was 2.5%, but when we considered only metastatic cases, it reached the 50%. SF3B1 variants correlated with significantly larger tumour size; higher Ki67 proliferation index; multiple treatments, including radiotherapy and chemotherapy; increased disease-specific death; and shorter postoperative survival. **Conclusions:** SF3B1 variants are uncommon in lactotroph tumours but may be frequent in metastatic lactotroph tumours. When present, they associate with aggressive tumour behaviour and worse clinical outcome. © The Author(s) 2023. Published by Oxford University Press on behalf of European Society of Endocrinology. All rights reserved.

Author Keywords

aggressive; carcinoma; lactotroph tumour; prolactinoma; SF3B1

Index Keywords

Ki 67 antigen, nucleic acid binding protein, prolactin, splicing factor 3b1, unclassified drug, phosphoprotein, RNA splicing factor, SF3B1 protein, human, transcription factor; adult, Article, cancer chemotherapy, cancer radiotherapy, cohort analysis, disease specific survival, exon, female, genetic association, histopathology, human, hypophysis tumor, major clinical study, male, metastasis, prevalence, primary tumor, prolactin blood level, prolactinoma, proliferation index, retrospective study, Sanger sequencing, tumor volume, clinical trial, genetics, hypophysis tumor, multicenter study, prevalence, prolactin secreting cell; Humans, Lactotrophs, Phosphoproteins, Pituitary Neoplasms, Prevalence, Retrospective Studies, RNA Splicing Factors, Transcription Factors

Correspondence Address

Theodoropoulou M.; Medizinische Klinik und Poliklinik IV, Ziemssenstr. 5, Germany; email: marily.theodoropoulou@med.uni-muenchen.de

Publisher: Oxford University Press

ISSN: 08044643

CODEN: EJOEE

PubMed ID: 37721395

Language of Original Document: English

Abbreviated Source Title: Eur. J. Endocrinol.

2-s2.0-85171513318

Document Type: Article

Publication Stage: Final

Source: Scopus